Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Fig. 2

Proportion of patients who achieved a ACR20, b ACR50, and c ACR70 improvement responses at weeks 12, 24, and 52. *p < 0.05, **p < 0.01, ***p < 0.001 Cochran-Mantel-Haenszel test stratified by prior biologic use and weight (< 55 kg, ≥ 55 kg) versus placebo at week 24. Patients were considered nonresponders from the time they started rescue medication or discontinued study medication. Primary endpoint was the proportion of patients achieving ACR20 response at week 24. ACR20/50/70 American College of Rheumatology 20%/50%/70% improvement criteria, MTX methotrexate, q2w every 2 weeks, SE standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us